Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04850846 · ClinicalTrials.gov registry record · Phase 2
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
A Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT04850846: Active Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Dana-Farber Cancer Institute.
NCT04850846 is a Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 60 participants, below the 797-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04850846, a Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma. The names of the study drug involved in this study is: * Metformin, extended release * Placebo ( a pill that has no active ingredients)
Primary Outcome
Assessed by using the serum-protein electrophoresis
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Metformin XR
Study Locations (7)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
- Dana-Farber at Brighton - Brighton
- Dana-Farber at Merrimack Valley - Methuen
- Dana-Farber at Milford - Milford
- DF/ BWCC in Clinical Affiliation with South Shore Hospital - Weymouth
New Hampshire
- Dana-Farber at NHOH - Londonderry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
What the registry record for NCT04850846 still lists
NCT04850846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 797-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04850846 lists 7 locations in 2 states (Massachusetts, New Hampshire).
Frequently Asked Questions
What is clinical trial NCT04850846 about?
NCT04850846 is a clinical study titled "Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma". The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma. The names of the study drug involved i...
What is the current status of trial NCT04850846?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-04-27. Estimated completion is 2027-07-31.
What conditions does trial NCT04850846 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance.
What interventions are being tested in trial NCT04850846?
The interventions under investigation include: Placebo (OTHER), Metformin XR (DRUG).
Who is sponsoring clinical trial NCT04850846?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04850846 being conducted?
This trial has 7 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04850846's enrollment target sits among peer trials
60 14th of 20 higher than 7 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
ACTIVE NOT RECRUITING · Phase 2
-
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI